BELLICUM PHARMACEUTICALS INC's ticker is BLCM and the CUSIP is 079481107. A total of 81 filers reported holding BELLICUM PHARMACEUTICALS INC in Q2 2019. The put-call ratio across all filers is 1.09 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2019 | $197,000 | +15.2% | 58,600 | 0.0% | 0.00% | – |
| Q4 2018 | $171,000 | -52.6% | 58,600 | 0.0% | 0.00% | – |
| Q3 2018 | $361,000 | -16.4% | 58,600 | 0.0% | 0.00% | – |
| Q2 2018 | $432,000 | +48.5% | 58,600 | +32.3% | 0.00% | – |
| Q1 2018 | $291,000 | -22.0% | 44,300 | 0.0% | 0.00% | – |
| Q4 2017 | $373,000 | -27.1% | 44,300 | 0.0% | 0.00% | -100.0% |
| Q3 2017 | $512,000 | -1.0% | 44,300 | 0.0% | 0.00% | 0.0% |
| Q2 2017 | $517,000 | -5.5% | 44,300 | 0.0% | 0.00% | 0.0% |
| Q1 2017 | $547,000 | +37.1% | 44,300 | +51.2% | 0.00% | 0.0% |
| Q4 2016 | $399,000 | -31.6% | 29,300 | 0.0% | 0.00% | 0.0% |
| Q3 2016 | $583,000 | +53.4% | 29,300 | 0.0% | 0.00% | 0.0% |
| Q2 2016 | $380,000 | +19.1% | 29,300 | -17.0% | 0.00% | 0.0% |
| Q1 2016 | $319,000 | -45.6% | 35,300 | +22.1% | 0.00% | 0.0% |
| Q4 2015 | $586,000 | +39.5% | 28,900 | 0.0% | 0.00% | 0.0% |
| Q3 2015 | $420,000 | +181.9% | 28,900 | +312.9% | 0.00% | – |
| Q2 2015 | $149,000 | – | 7,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Avoro Capital Advisors LLC | 220,000 | $5,069,000 | 3.43% |
| Perceptive Advisors | 1,046,402 | $24,109,000 | 2.02% |
| Redmile Group, LLC | 860,809 | $17,269,000 | 1.88% |
| Baker Brothers Advisors | 4,283,732 | $98,697,000 | 1.01% |
| RA Capital Management | 1,026,402 | $9,337,000 | 1.00% |
| Ghost Tree Capital, LLC | 75,000 | $1,728,000 | 0.83% |
| ACUTA CAPITAL PARTNERS, LLC | 45,750 | $1,054,000 | 0.71% |
| GREAT POINT PARTNERS LLC | 50,000 | $1,152,000 | 0.55% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 167,210 | $3,853,000 | 0.33% |
| EMERALD ADVISERS, LLC | 198,202 | $4,567,000 | 0.24% |